Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer

Fig. 2

Histological and molecular analysis of PDOs. A H&E (hematoxylin/eosin) staining of tumor and matching PDO. Scale Bar, 250 μm. B CNA representation of an MSS PDO (left panel) and an MSI PDO (right panel). Blue and Red indicate gain and loss regions respectively. C CNA of the 25 PDO lines for 7 chromosome arms frequently altered in CRC carcinogenesis. D Oncogenic somatic mutations of the PDOs for 18 genes and comparison with available molecular alterations of matching tumors. The percentage of each mutation in the PDO cohort is compared to the percenatge of mutations observed in the cosmic cohort. MS*: The missense PIK3CA mutation is found in the tumor tissue but not in the matching CGR0011 PDO. The gene panels tested on tumor tissues are detailed in Supplementary Table 2

Back to article page